ERBB4 and breast cancer: Recent studies show the significant role of both ErbB3 and ErbB4 as alternative targets for the treatment of breast cancer patients suggesting a pan-ErbB inhibitor strategy that is able to interfere the cross-talk between the various ErbB receptors [79].